NEW HAVEN, Conn., June 08, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today ...

Novartis, whose presence in prostate cancer is mainly through the radiopharmaceutical Pluvicto, is expanding its prospects in the disease, striking a deal that brings a Phase 3-ready small molecule in ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Real estate investors often consider the after-repair value, or ARV, of a piece of real estate when deciding whether a deal is worth pursuing. The ARV is an estimate of what the property will be worth ...

Arvinas, Inc. announced promising preclinical results for ARV-393, a targeted protein degrader aimed at treating non-Hodgkin lymphoma, particularly high grade B-cell lymphomas. Data showed that ...

Arvinas, Inc. (NASDAQ:ARVN) unveiled first-in-human data on Friday for its experimental Parkinson’s disease treatment, ARV-102. Results from the randomized, double-blind, placebo-controlled single ...

Arvinas, Inc., a biotechnology company focused on targeted protein degradation therapies, announced that new preclinical data for its investigational drug ARV-393 will be presented at the upcoming ...

Ugandan HIV activists Barbara Kemigisa shows Antiretroviral (ARV) packagings and tablets in an art design encouraging people infected with HIV to use the ARVs and fight against stigmatisation during ...